![Revance Therapeutics, Inc. [RVNC] reports annual net loss of $323,986,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FRVNC.png&w=3840&q=75)
Revance Therapeutics, Inc. [RVNC] reports annual net loss of $323,986,000.0
Company Reports Revenue of $234.0 million
By USInMinutes
Published - Feb 29, 2024, 05:32 AM ET
Last Updated - Feb 29, 2024, 05:32 AM EST
Revance Therapeutics, Inc. [RVNC] has reported a net loss of $323,986,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $234.0 million
Based in NASHVILLE, Tennessee, Revance Therapeutics, Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations and Comprehensive Loss for the 12 months ended December 31, 2023, compared to the previous years, the following financial results were observed:
- Revenue for the period ending December 31, 2023, was $234.04 million, showing significant growth compared to $132.57 million in 2022 and $77.80 million in 2021.
